Data Sheet (Cat.No.T16751)

TargetMol

Rilapladib

Chemical Properties



CAS No. : 412950-08-4

Formula: C40H38F5N3O3S

Molecular Weight: 735.8

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2, IC50 = 230 pM) and acts as an antagonist of the platelet-activating factor receptor.
Targets(IC50)	Phospholipase
In vitro	Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2].

Solubility Information

Solubility	DMSO: 150 mg/mL (203.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.72 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3591 mL	6.7953 mL	13.5906 mL
5 mM	0.2718 mL	1.3591 mL	2.7181 mL
10 mM	0.1359 mL	0.6795 mL	1.3591 mL
50 mM	0.0272 mL	0.1359 mL	0.2718 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A_2 inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.
Athanasios Papakyriakou, et al. Computational Investigation of Darapladib and Rilapladib Binding to Platelet Activating Factor Receptor. A Possible Mechanism of Their Involvement in Atherosclerosis. International Journal of Chemistry; Vol. 6, No. 1; 2014.